These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30776883)

  • 41. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
    Grosso F; D'Ambrosio L; Zucchetti M; Ibrahim T; Tamberi S; Matteo C; Rulli E; Comandini D; Palmerini E; Baldi GG; DeCensi A; Bergaglio M; Marra D; Marchesi E; Siri G; D'Incalci M; Grignani G
    Cancer; 2020 Nov; 126(21):4726-4734. PubMed ID: 32749681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T
    Crombé A; Périer C; Kind M; De Senneville BD; Le Loarer F; Italiano A; Buy X; Saut O
    J Magn Reson Imaging; 2019 Aug; 50(2):497-510. PubMed ID: 30569552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patterns of Care and Survival in Elderly Patients With Locally Advanced Soft Tissue Sarcoma.
    Greto D; Saieva C; Loi M; Desideri I; Delli Paoli C; Lo Russo M; Pezzulla D; Teriaca MA; Lucidi S; Visani L; Terziani F; Olmetto E; Becherini C; Bonomo P; Francolini G; Campanacci DA; Scoccianti G; Livi L
    Am J Clin Oncol; 2019 Oct; 42(10):749-754. PubMed ID: 31503061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.
    Kroep JR; Ouali M; Gelderblom H; Le Cesne A; Dekker TJA; Van Glabbeke M; Hogendoorn PCW; Hohenberger P
    Ann Oncol; 2011 Jan; 22(1):207-214. PubMed ID: 20656792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiological aspects of soft tissue sarcomas (STS)--consequences for the design of clinical STS trials.
    Nijhuis PH; Schaapveld M; Otter R; Molenaar WM; van der Graaf WT; Hoekstra HJ
    Eur J Cancer; 1999 Nov; 35(12):1705-10. PubMed ID: 10674017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current trials and new aspects in soft tissue sarcoma of adults.
    Issels RD; Schlemmer M
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
    Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
    Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regional variation in the survival of patients with a soft-tissue sarcoma of the extremity and trunk wall under a centralized care system : what has been the impact of national policies in the UK?
    Fujiwara T; Evans S; Stevenson J; Tsuda Y; Gregory J; Grimer RJ; Abudu S
    Bone Joint J; 2021 Sep; 103-B(9):1541-1549. PubMed ID: 34465152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcomes of non-osteogenic, non-Ewing soft-tissue sarcoma of bone--experience of the Toronto Sarcoma Program.
    Veitch ZW; Fasih S; Griffin AM; Al-Ezzi EM; Gupta AA; Ferguson PC; Wunder JS; Abdul Razak AR
    Cancer Med; 2020 Dec; 9(24):9282-9292. PubMed ID: 33063945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
    Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
    Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
    Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
    Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence of soft tissue sarcoma in Taiwan: A nationwide population-based study (2007-2013).
    Hung GY; Horng JL; Chen PC; Lin LY; Chen JY; Chuang PH; Chao TC; Yen CC
    Cancer Epidemiol; 2019 Jun; 60():185-192. PubMed ID: 31055220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A demographic and clinical panorama of a sixteen-year cohort of soft tissue sarcoma patients in Brazil.
    de Figueiredo LO; Júnior AAG; de Assis Acurcio F; Almeida AM; Cherchiglia ML; Wainstein AJA; Thuler LCS; Nogueira-Rodrigues A
    Sci Rep; 2021 Nov; 11(1):22501. PubMed ID: 34795383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Curability of patients with lymph node metastases from extremity soft-tissue sarcoma.
    Basile G; Mattei JC; Alshaygy I; Griffin AM; Catton CN; Chung PW; Shultz DB; Razak ARA; Demicco EG; Ferguson PC; Wunder JS
    Cancer; 2020 Dec; 126(23):5098-5108. PubMed ID: 32910462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High cumulative doxorubicin dose for advanced soft tissue sarcoma.
    Tian Z; Yang Y; Yang Y; Zhang F; Li P; Wang J; Yang J; Zhang P; Yao W; Wang X
    BMC Cancer; 2020 Nov; 20(1):1139. PubMed ID: 33228579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey.
    Rothermundt C; Fischer GF; Bauer S; Blay JY; Grünwald V; Italiano A; Kasper B; Kollár A; Lindner LH; Miah A; Sleijfer S; Stacchiotti S; Putora PM
    Oncologist; 2018 Apr; 23(4):461-467. PubMed ID: 29192019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
    Zhang XY; Liu J; Deng YT; Jiang Y
    Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
    Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
    Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
    Martin-Broto J; Gutierrez AM; Ramos RF; Lopez-Guerrero JA; Ferrari S; Stacchiotti S; Picci P; Calabuig S; Collini P; Gambarotti M; Bague S; Dei Tos AP; Palassini E; Luna P; Cruz J; Cubedo R; Martinez-Trufero J; Poveda A; Casali PG; Fernandez-Serra A; Lopez-Pousa A; Gronchi A
    Mol Cancer Ther; 2014 Jan; 13(1):249-59. PubMed ID: 24145283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.